Antibody cocktail
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties